Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07255482 · ClinicalTrials.gov registry record
Mortality Benefit of Ultrasound for Thyroid Nodules Identified With PET Imaging: Non-Inferiority Emulated Target Trial
A clinical trial of Thyroid Cancer and Thyroid Nodule (Benign), sponsored by Brigham and Women's Hospital.
- Active
- Registry status
- 5,000
- Enrollment target
- 1
- Study location
NCT07255482: Active study of Thyroid Cancer and Thyroid Nodule (Benign), sponsored by Brigham and Women's Hospital.
NCT07255482 is a study of Thyroid Cancer and Thyroid Nodule (Benign) that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 5,000 participants, above the 173-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (2790% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07255482, a study of Thyroid Cancer and Thyroid Nodule (Benign), is active but no longer recruiting, sponsored by Brigham and Women's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- 5,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators hypothesize that all-cause mortality in patients with an incidental thyroid nodule on PET-CT who did not have thyroid ultrasound (the exposure) within 3 months of the PET-CT is non-inferior within a 5% margin to those who have thyroid ultrasound at 7-years. That is, among patients with an incidental thyroid nodule on PET-CT, mortality is no more than 5% larger (in absolute difference) for those who do not have thyroid ultrasound compared to those who do. The investigators will also report mortality differences at landmark timeframes of 1-year, 3-years, 5-years, and 10-years. To estimate group differences in mortality, the investigators will conduct a non-inferiority emulated target trial utilizing clone-censor weighting to address potential immortal time bias introduced by the 3-month grace period. The investigators will adjust for demographic, potential confounder, and mortality risk adjustor factors. The investigators will stratify analyses based on baseline disease severity (estimated 5-year relative survival risk) and disease status (progression, lymph node involvement, other sites of metastases). All subjects will be accrued from the Mass General Brigham healthcare system, which includes two academic medical centers, a specialty head and neck hospital, and multiple community hospitals and numerous community clinics.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Thyroid Ultrasound
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2025-10-15 |
| Est. Completion | 2026-03-31 |
What the registry record for NCT07255482 still lists
NCT07255482 is an observational study that tracks outcomes without assigning an intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus, above the 173-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (2790% higher).
The record links to 3 conditions, with Thyroid Cancer appearing as the primary indexed condition, and to 1 intervention - of which Thyroid Ultrasound is the first listed.
NCT07255482 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07255482 about?
NCT07255482 is a clinical study titled "Mortality Benefit of Ultrasound for Thyroid Nodules Identified With PET Imaging: Non-Inferiority Emulated Target Trial". The investigators hypothesize that all-cause mortality in patients with an incidental thyroid nodule on PET-CT who did not have thyroid ultrasound (the exposure) within 3 months of the PET-CT is non-inferior within a 5% margin to those who have thyroid ultrasound at 7-years. That is, among patients ...
What is the current status of trial NCT07255482?
This trial is currently active not recruiting. The enrollment target is 5,000 participants. The study started on 2025-10-15. Estimated completion is 2026-03-31.
What conditions does trial NCT07255482 study?
This clinical trial studies the following conditions: Thyroid Cancer, Thyroid Nodule (Benign), Thyroid Nodule (Diagnosis).
What interventions are being tested in trial NCT07255482?
The interventions under investigation include: Thyroid Ultrasound (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07255482?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07255482 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07255482's enrollment target sits among peer trials
5,000 1st of 46 higher than 46 of 46 other Thyroid Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thyroid Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
RECRUITING · Phase 2
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer
RECRUITING
-
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00060541 · 5,000 participants
Evaluation and Treatment of Neurosurgical Disorders
- NCT00575081 · 5,000 participants
Physiological Brain Atlas Development
- NCT00736749 · 5,000 participants
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
- NCT00900198 · 5,000 participants
Collection of Tissue Samples for Cancer Research
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI